Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Dr. Christopher Cutie shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, HR NMIBC.
Dr. Christopher Cutie describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery.
Results of the phase III BOND-003 trial show groundbreaking results of cretostimogene grenadenorepvec for NMIBC.
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.